Tempest Therapeutics, Inc. SEC filings TPST
Tempest Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Feb 1, 2013. Its latest annual report, Form ARS, was filed on Nov 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Oct 14, 2026 | — |
| EFFECT | Filing | Oct 1, 2026 | — |
| EFFECT | Filing | Aug 31, 2026 | — |
| CORRESP | Letter to the SEC | Aug 27, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2026 | — |
| EFFECT | Filing | Jul 7, 2026 | — |
| CORRESP | Letter to the SEC | Jul 2, 2026 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2026 | — |
| D | Filing | Jun 23, 2026 | — |
| EFFECT | Filing | Apr 9, 2026 | — |
| CORRESP | Letter to the SEC | Apr 8, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2026 | — |
| EFFECT | Filing | Apr 3, 2026 | — |
| D | Filing | Apr 3, 2026 | — |
| CORRESP | Letter to the SEC | Apr 1, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2026 | — |
| EFFECT | Filing | Dec 31, 2025 | — |
| CORRESP | Letter to the SEC | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2025 | — |
| EFFECT | Filing | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 24, 2025 | — |
| 8-A12B/A | Filing | Oct 10, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2024 | — |
| 8-A12B | Filing | Oct 11, 2023 | — |
| EFFECT | Filing | May 27, 2022 | — |
| CORRESP | Letter to the SEC | May 24, 2022 | — |
| UPLOAD | Letter from the SEC | May 18, 2022 | — |
| D | Filing | May 11, 2022 | — |
| EFFECT | Filing | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 22, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2021 | — |
| 425 | 8-k | Jun 11, 2021 | — |
| EFFECT | Filing | May 11, 2021 | — |
| CORRESP | Letter to the SEC | May 7, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2021 | — |
| 425 | Form 8-k | Mar 29, 2021 | — |
| EFFECT | Filing | Apr 18, 2019 | — |
| CORRESP | Letter to the SEC | Apr 16, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2019 | — |
| EFFECT | Filing | Dec 6, 2018 | — |
| CORRESP | Letter to the SEC | Dec 3, 2018 | — |
| 425 | 8-k | Nov 30, 2018 | — |
| 425 | 8-k | Nov 26, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2018 | — |
| 425 | 8-k | Nov 19, 2018 | — |
| CORRESP | Letter to the SEC | Nov 16, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2018 | — |
| CT ORDER | Filing | Nov 7, 2018 | — |
| EFFECT | Filing | Nov 5, 2018 | — |
| CORRESP | Letter to the SEC | Nov 1, 2018 | — |
| 425 | 8-k | Nov 1, 2018 | — |
| 425 | 8-k | Aug 9, 2018 | — |
| CT ORDER | Filing | May 15, 2018 | — |
| CT ORDER | Filing | Apr 30, 2018 | — |
| RW | Filing | Mar 15, 2018 | — |
| CT ORDER | Filing | Jan 27, 2017 | — |
| EFFECT | Filing | May 5, 2016 | — |
| CORRESP | Letter to the SEC | May 4, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2016 | — |
| CT ORDER | Filing | May 19, 2015 | — |
| EFFECT | Filing | Nov 21, 2014 | — |
| CT ORDER | Filing | Apr 29, 2014 | — |
| EFFECT | Filing | Sep 10, 2013 | — |
| EFFECT | Filing | Sep 10, 2013 | — |
| EFFECT | Filing | Sep 10, 2013 | — |
| CT ORDER | Filing | Aug 30, 2013 | — |
| EFFECT | Filing | May 20, 2013 | — |
| CERTNAS | Auto-generated paper document | Apr 29, 2013 | — |
| 8-A12B | Filing | Apr 25, 2013 | — |
| D | Filing | Mar 28, 2013 | — |
| EFFECT | Filing | Mar 5, 2013 | — |
Showing 72 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TPST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc. (until Jul 1, 2021); OvaScience, Inc. (until Dec 6, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.